Related Experiment Video
Updated: Jun 13, 2026
Understanding the Development of Compensatory Pathways in a Mutant Malaria Parasite Harbouring Hypomorphic Allele of Plant-Like Kinases
Published on: November 22, 2024
Expression, purification and characterization of allelic variants of MSP-1(42) from Indian Plasmodium falciparum
P V Lalitha1, S Biswas, C R Pillai
1School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India. lalithapv@hotmail.com
Abstract:
The C-terminal 19 and 42 kDa fragments of Plasmodium falciparum merozoite surface protein 1 (MSP-1) have shown to be protective in animals against lethal parasite challenge. The MSP-1(19) being highly conserved may lack sufficient number of T-cell epitopes in order to elicit a broader response in genetically diverse populations. The inclusion of additional epitopes from the N-terminal MSP-1(42) has shown to enhance the protective efficacy of MSP-1(19) vaccine. In an attempt to examine the strain specific immunogenicity to MSP-1, we have cloned and expressed three diverse allelic variants of MSP-1(42) from Indian P. falciparum isolates in bacteria. Among three alleles, one was extremely rare and not been found before. These purified and refolded recombinant products were recognized by conformation specific monoclonal antibodies and hyper-immune sera. Immunization of mice and rabbits with the purified proteins generated high titer biologically active polyclonal antibodies supporting further development of this vaccine candidate antigen.
Insights
This study explored Plasmodium falciparum merozoite surface protein 1 (MSP-1) fragments for malaria vaccine development. Researchers found that combining MSP-1(42) variants with MSP-1(19) enhances immune responses, supporting further vaccine research.
Area of Science:
- Immunology
- Parasitology
- Vaccine Development
Background:
- The C-terminal 19 kDa (MSP-1(19)) and 42 kDa (MSP-1(42)) fragments of Plasmodium falciparum merozoite surface protein 1 (MSP-1) show protective immunity in animal models.
- MSP-1(19) is conserved but may have limited T-cell epitopes for broad efficacy in diverse populations.
- Combining MSP-1(42) epitopes with MSP-1(19) can improve vaccine effectiveness.
Purpose of the Study:
- To investigate the strain-specific immunogenicity of MSP-1.
- To clone and express diverse allelic variants of MSP-1(42) from Indian Plasmodium falciparum isolates.
- To evaluate the potential of these variants as vaccine candidates.
Main Methods:
- Cloning and bacterial expression of three distinct MSP-1(42) allelic variants.
- Purification and refolding of recombinant proteins.
- Characterization using monoclonal antibodies and hyper-immune sera.
- Immunization of mice and rabbits to assess antibody responses.
Main Results:
- Successfully cloned and expressed three MSP-1(42) allelic variants, including a previously undiscovered rare allele.
- Purified recombinant proteins were recognized by specific antibodies, confirming their structure and antigenicity.
- Immunization induced high titers of biologically active polyclonal antibodies in mice and rabbits.
Conclusions:
- The expressed MSP-1(42) variants are immunogenic and recognized by specific antibodies.
- These findings support the further development of MSP-1(42) allelic variants as components of a malaria vaccine.
- The inclusion of diverse MSP-1(42) epitopes may broaden the immune response against Plasmodium falciparum.
